FOR IMMEDIATE RELEASE: December 13, 2023 MAPS Public Benefit Corporation (MAPS PBC) formally submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) which included data from …
FOR IMMEDIATE RELEASE: September 14, 2023 Results of the second, confirmatory Phase 3 trial of MDMA-assisted therapy for posttraumatic stress disorder, MAPP2, have been published in Nature Medicine. MAPP2 …
MDMA has been gaining attention for its potential therapeutic applications. In recent years, MDMA therapy, particularly MDMA-assisted psychotherapy, has been a topic of extensive research, with MAPS’ …
Quote Originally appearing here (Archived)
FOR IMMEDIATE RELEASE: April 5, 2023 MAPS Public Benefit Corporation (MAPS PBC), a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), announced preliminary findings …
The world's most advanced psychedelic-assisted therapy trial has confirmed positive findings in the second Phase 3 trial of MDMA-assisted therapy for PTSD.
Since the final participant for this MAPP2 was treated on November 17, 2022, the database has been locked and is being analyzed. This study is our second Phase 3 trial of MDMA-assisted therapy for posttraumatic …
MAPS Public Benefit Corporation (MAPS PBC) has announced that the final participant in the second Phase 3 trial of psychedelic-assisted therapy, A Multi-Site Phase 3 Study of MDMA-Assisted Therapy for …
FOR IMMEDIATE RELEASE: May 9, 2022 The second, confirmatory Phase 3 trial of MDMA-assisted therapy for PTSD is now fully enrolled at 13 sites in the United States and Israel Completion of enrollment on …
On March 22, 2022, all study sites have met the criteria to provide treatment in the cross-over extension study for MAPS-sponsored Phase 3 trials of MDMA-assisted therapy for posttraumatic stress disorder …
On February 28, 2022, the thirteenth study site in our multi-site open-label extension study of MDMA-assisted therapy for PTSD (MAPPUSX) officially began screening potential study participants. This study …
On February 3, our Phase 3 study site for MDMA-assisted psychotherapy for PTSD in Tel Hashomer, Israel, officially opened for phone screenings and informed consent visits. Led by Principal Investigator …
